Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Nov;60(5):526-33.
doi: 10.1111/j.1365-2125.2005.02463.x.

General practitioners' adoption of new drugs and previous prescribing of drugs belonging to the same therapeutic class: a pharmacoepidemiological study

Torben Dybdahl  1 , Morten Andersen, Jakob Kragstrup, Ivar Sønbø Kristiansen, Jens Søndergaard
Affiliations

General practitioners' adoption of new drugs and previous prescribing of drugs belonging to the same therapeutic class: a pharmacoepidemiological study

Torben Dybdahl et al. Br J Clin Pharmacol. 2005 Nov.

Abstract

Aim: To test the hypothesis that general practitioners (GPs) with high prescribing levels of certain drugs will adopt new drugs belonging to the same therapeutic group faster than those with low prescribing levels.

Methods: The adoption of four new drugs: esomeprazol, selective cyclo-oxygenase-2 inhibitors, new triptans, and angiotensin-II receptor blockers were analysed using population-based prescription data. We used the preference proportion (prescriptions for new rather than older alternatives for the same indication) to measure GPs' adoption rate. Annual prescribing volume and prevalence were used to measure previous prescribing of older drug alternatives. We modelled the preference proportion using multiple linear regression analysis and the prescribing of older drugs as independent variables. We controlled for the GPs' general prescribing level and weighted for practice size. In the first three analyses, we dichotomized data using the median, lower and upper quartile as cut-off point. Next, we grouped data into quartiles and finally, we used continuous data.

Results: For esomeprazol and new triptans there was a higher preference for new drugs among "high prescribers", but only when this term was defined as the upper quarter and the upper half of previous prescribing levels, respectively (mean difference in preference proportion: 10.2% (99% confidence interval = 1.3%, 19.1%) and 8.2% (0.2%, 16.2%)). For the remaining two drug classes the associations were weak and almost all statistically nonsignificant.

Conclusion: There is no consistent association between GPs' level of drug prescribing and their adoption of new drugs of the same therapeutic group.

PubMed Disclaimer

Comment in

  • Prescribing statins.
    Aronson JK. Aronson JK. Br J Clin Pharmacol. 2005 Nov;60(5):457-8. doi: 10.1111/j.1365-2125.2005.02521.x. Br J Clin Pharmacol. 2005. PMID: 16236034 Free PMC article. No abstract available.

References

    1. Pedersen KM. Pricing and reimbursement of drugs in Denmark. Eur J Health Econom. 2003;4:60–5. - PubMed
    1. Davis P, Gribben B. Rational prescribing and interpractitioner variation. A multilevel approach. Int J Technol Assess Health Care. 1995;11:428–42. - PubMed
    1. Washington DC: The Institute; 2002. The National Institute for Health Care Management Research and Educational Foundation Changing Patterns of Pharmaceutical Innovation.
    1. The National Institute for Health Care Management Research and Educational Foundation. Prescription Drug Expenditure 2000: The Upward Trend Continues. Washington DC: The Institute; 2001.
    1. McGavock H, Wenn CH, Johnston GD, Milligan E. Market penetration of new drugs in one United Kingdom region. implications for general practitioners and administrators. BMJ. 1993;307:1118–20. - PMC - PubMed

Publication types